XisGe^® technology is suitable for improving the local duration of action for short half-life drugs to allows in vivo sustained release for 3 to 7 days and has very low difficulties of manufacturing control and scale up and advantage of dosing convenience. The excipients used are all included in the FDA IIG (Inactive Ingredients Database), which provides excellent prescription safety and good drug-forming properties.

ETPF^® technology is suitable for improving the bioavailability and ease of use for topical formulations by greatly enhancing drug solubility and transdermal rate through our proprietary prescriptions, and drug compliance can thus be facilitated as well.